Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 3Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Carcinoma, Non-Small-Cell Lung 3Recurrence 2Myelodysplastic Syndromes 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Acute 2Hodgkin Disease 2Stomach Neoplasms 1Prostatic Neoplasms 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma 1Lung Neoplasms 1Leukemia 1Breast Neoplasms 1

Interventions

Cyclophosphamide 39fludarabine phosphate 37Azacitidine 33fludarabine 25Whole-Body Irradiation 22Busulfan 22Tacrolimus 21Antilymphocyte Serum 21Mycophenolic Acid 19Filgrastim 18Methotrexate 16Melphalan 15venetoclax 13Peripheral Blood Stem Cell Transplantation 13Granulocyte Colony-Stimulating Factor 13Cytarabine 13thymoglobulin 12Cyclosporine 12Thiotepa 9Cord Blood Stem Cell Transplantation 9Alemtuzumab 8Rituximab 7Radiotherapy 7Methylprednisolone 7Decitabine 7Clofarabine 7Lenalidomide 6Stem Cell Transplantation 5Sirolimus 5Nivolumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Myelodysplastic Syndromes × mocetinostat × Clear all
NCT00374296 2015-07-01

MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease

Mirati Therapeutics Inc.

Phase 2 Terminated
35 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT00666497 2015-05-08

Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Mirati Therapeutics Inc.

Phase 2 Terminated
6 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡